论文部分内容阅读
革兰阴性菌脓毒性休克的死亡率高达50～80%,应用抗生素和皮质类固醇治疗也不能降低。Ziegler等报道,使用抗大肠杆菌J5粗糙型突变株血清能明显地降低革兰阴性菌血症和休克的死亡率。但此血清不是冻干纯化制剂,不能长期保存,在治疗应用上受到限制;而它的冻干纯制品不但能长期保存,而且可作静脉滴注。为了验证抗大肠杆菌J5株的人IgG抗体的冻干制品(J5-INIG)的疗效,作者在8家瑞士和两家荷兰医疗中心进行了一项随机双盲试验,旨在比较J5-IVIG与标准IgG制剂
Gram-negative bacterial septic shock mortality as high as 50 to 80%, the application of antibiotics and corticosteroids can not be reduced. Ziegler et al reported that the use of anti-Escherichia coli J5 rough mutant serum can significantly reduce Gram-negative bacteremia and shock mortality. However, this serum is not a freeze-dried purified preparation, can not be stored for a long time, and is limited in therapeutic applications. The lyophilized pure product can not only be preserved for a long time, but also can be used as an intravenous drip. To validate the efficacy of freeze-dried preparations of human IgG against Escherichia coli strain J5 (J5-INIG), the authors conducted a randomized double-blind trial in 8 Swiss and two Dutch medical centers to compare J5-IVIG with Standard IgG preparations